Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells 328 Shares of Stock

January 9, 2026 by InsiderTrades.com

Key Points

CEO Jack Bendheim sold 328 shares on Jan. 7 at $40.09 for $13,149, leaving him with 38,872 shares (a 0.84% reduction); this sale continues a string of large insider disposals in Nov–Dec that included multiple transactions of tens of thousands of shares.
Recent results and guidance: Phibro beat Q3 estimates with $0.73 EPS (vs. $0.58 expected) and set FY2026 guidance of $2.640–$2.810 EPS, and it pays a $0.12 quarterly dividend ($0.48 annualized, ~1.2% yield).
Market and analyst view: PAHC trades near $39.72 (50-day MA $40.89, 200-day MA $36.40) with a ~$1.61B market cap and ~23.9x PE, while analysts’ consensus is a "Hold" with a $31.40 target despite some firms raising targets to as high as $50.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 328 shares of Phibro Animal Health stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $40.09, for a total transaction of $13,149.52. Following the completion of the transaction, the chief executive officer directly owned 38,872 shares of the company's stock, valued at approximately $1,558,378.48. This trade represents a 0.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jack Bendheim also recently made the following trade(s):

On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.93, for a total transaction of $235,429.36.
On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.19, for a total value of $51,764.72.
On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total transaction of $141,011.20.
On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total transaction of $143,510.40.
On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $43.93, for a total value of $309,267.20.
On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.02, for a total value of $232,425.60.
On Monday, November 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.56, for a total value of $235,276.80.
On Thursday, November 13th, Jack Bendheim sold 8,801 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.47, for a total transaction of $391,380.47.
On Wednesday, November 12th, Jack Bendheim sold 21,536 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.23, for a total transaction of $974,073.28.
On Monday, November 10th, Jack Bendheim sold 38,303 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.29, for a total transaction of $1,734,742.87.

Phibro Animal Health Stock Up 0.7%

NASDAQ PAHC opened at $39.72 on Friday. The business has a fifty day moving average price of $40.89 and a two-hundred day moving average price of $36.40. The stock has a market capitalization of $1.61 billion, a PE ratio of 23.93, a PEG ratio of 1.12 and a beta of 0.79. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $46.42. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.15. The firm had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th were paid a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, November 26th. This represents a $0.48 annualized dividend and a yield of 1.2%. Phibro Animal Health's dividend payout ratio is currently 28.92%.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL boosted its stake in shares of Phibro Animal Health by 3.4% during the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company's stock valued at $412,000 after purchasing an additional 338 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Phibro Animal Health by 2.9% in the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company's stock worth $332,000 after buying an additional 363 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Phibro Animal Health by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company's stock worth $260,000 after acquiring an additional 546 shares during the last quarter. Prospera Financial Services Inc lifted its position in Phibro Animal Health by 3.6% in the 2nd quarter. Prospera Financial Services Inc now owns 19,910 shares of the company's stock valued at $508,000 after acquiring an additional 690 shares in the last quarter. Finally, Intech Investment Management LLC raised its stake in shares of Phibro Animal Health by 8.2% in the third quarter. Intech Investment Management LLC now owns 9,147 shares of the company's stock worth $370,000 after purchasing an additional 697 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on PAHC shares. JPMorgan Chase & Co. upped their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an "overweight" rating in a report on Friday, November 7th. Zacks Research raised Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings restated a "buy (b-)" rating on shares of Phibro Animal Health in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $31.40.

Read Our Latest Research Report on Phibro Animal Health

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.